Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

New MedPredict Report Reveals Top Alzheimer's Experts' Insights On Diagnostics And Treatments In Development Pipeline
MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report entitled "Thought Leader Insight & Analysis: Alzheimer"s Disease," designed to provide critical strategic insight for pharma and biotech companies with a stake in the market for diagnostics and treatments in this disease area.
generic viagra online
Yale Team Identifies Key To Potential New Treatment For Allergy-Induced Asthma
In research that could lead to new asthma drugs, scientists at Yale School of Medicine, Hydra Biosciences of Cambridge, Massachusetts, and the University of California, San Francisco have discovered that a protein may be a trigger of allergy-induced asthma in mice. They also demonstrated how a drug known to reduce inflammatory and neuropathic pain may also inhibit asthma symptoms in mice. Their paper is published in the May 18-22 online Early Edition of the Proceedings of the National Academy of Sciences.
News of the day
Millions Of People With Musculoskeletal Conditions At Risk Of Being Let Down By NHS
One-in-five (21%) primary care trusts (PCTs) do not offer "clinical assessment
Mental Health

Merck Partners With Non-Profit For Neglected Diseases Initiative

The pharmaceutical company, Merck, announced Monday it was partnering with the non-profit Drugs for Neglected Diseases initiative (DNDi) in an effort to improve treatments for neglected tropical diseases (NTD), the AP/CNBC reports. "The agreement covers drug candidates for illnesses like visceral leishmaniasis and Chagas disease, potentially lethal parasitic illnesses spread by insects. Current treatment for those illnesses may be toxic, or very expensive, or difficult to administer, Merck said," AP/CNBC writes (AP/CNBC, 6/22). RTT News reports, "Under terms of the agreement, Merck will contribute small molecule assets and related intellectual property via a non-exclusive, royalty-free license to DNDi to conduct early development programs for drug candidates for the treatment of NTDs like visceral leishmaniasis and Chagas disease" (RTT News, 6/22). In related news, Xinhua/CRIENGLISH.com reports on an international NTD meeting to be held Tuesday in Nairobi, Kenya. The meeting - sponsored by DNDi - will bring together researchers, clinicians and policymakers from around the world to discuss the latest research and drug development for NTD. "The meeting will also cement DNDi"s partnership with key players such as NGOs and leading African and international experts on infectious and neglected tropical diseases, according to Dr. Monique Wasunna, the assistant director," the news agency reports (Xinhua/CRIENGLISH.com, 6/22). This information was reprinted from globalhealth.kff.org with kind permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily Global Health Policy Report, search the archives and sign up for email delivery at globalhealth.kff.org. © Henry J. Kaiser Family Foundation. All rights reserved.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009